Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 3;8(1):102311.
doi: 10.1016/j.rpth.2023.102311. eCollection 2024 Jan.

Galectin-3-binding protein and future venous thromboembolism

Ellen-Sofie Hansen  1 , Magnus S Edvardsen  1 , Pål Aukrust  2   3   4 , Thor Ueland  1   2   3 , John-Bjarne Hansen  1   5 , Sigrid K Brækkan  1   5 , Vânia M Morelli  1   5
Affiliations

Galectin-3-binding protein and future venous thromboembolism

Ellen-Sofie Hansen et al. Res Pract Thromb Haemost. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Plasma levels of galectin-3-binding protein (gal3bp) and venous thromboembolism (VTE). (A) Odds ratios (OR) with 95% CI for venous thromboembolism (VTE) according to quartiles of gal3bp plasma levels. Model 1, adjusted for age and sex; model 2, adjusted for age, sex, and body mass index (BMI); model 3, adjusted for age, sex, BMI, and high-sensitivity C-reactive protein. Women, quartile 1: <3.42 μg/mL; quartile 2: 3.42-4.82 μg/mL; quartile 3: 4.82-6.71 μg/mL; and quartile 4: ≥6.71 μg/mL. Men, quartile 1: <2.92 μg/mL; quartile 2: 2.92-3.96 μg/mL; quartile 3: 3.96-5.20 μg/mL; and quartile 4: ≥5.20 μg/mL. (B) Plots of estimated ORs for overall VTE as a function of time from blood sampling in Tromsø 4 (1994-1995) to VTE events. Participants with plasma levels of gal3bp in the highest quartile (Q4) were compared with those with gal3bp in the lowest quartile (Q1, reference category). Analyses were adjusted for age, sex, BMI, and high-sensitivity C-reactive protein. Risk estimates were not statistically significant (P < .05). The number of VTE events is depicted above the plot. Note that because of a missing value in BMI, there were 414 VTE events when BMI was used as an adjustment variable.
See this image and copyright information in PMC

References

    1. Khan F., Tritschler T., Kahn S.R., Rodger M.A. Venous thromboembolism. Lancet. 2021;398:64–77. - PubMed
    1. Cushman M., Tsai A.W., White R.H., Heckbert S.R., Rosamond W.D., Enright P., et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19–25. - PubMed
    1. Diaz J.A., Ramacciotti E., Wakefield T.W. Do galectins play a role in venous thrombosis? A review. Thromb Res. 2010;125:373–376. - PMC - PubMed
    1. DeRoo E.P., Wrobleski S.K., Shea E.M., Al-Khalil R.K., Hawley A.E., Henke P.K., et al. The role of galectin-3 and galectin-3-binding protein in venous thrombosis. Blood. 2015;125:1813–1821. - PMC - PubMed
    1. Fashanu O.E., Heckbert S.R., Aguilar D., Jensen P.N., Ballantyne C.M., Basu S., et al. Galectin-3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study. Res Pract Thromb Haemost. 2017;1:223–230. - PMC - PubMed

LinkOut - more resources